Though Novo Nordisk had a first-mover advantage in the GLP-1 market, Eli Lilly is catching up. Lilly's recent clinical progress sets it up for another critical approval. The company has fantastic ...

Eli Lilly (NYSE:LLY) on Friday reported plans to acquire Adverum Biotechnologies (NASDAQ:ADVM) and its lead gene therapy candidate, Ixo-vec, sending Adverum shares soaring in premarket trading. Under ...

Eli Lilly is a leader in weight loss drugs, a market that may reach $95 billion by the end of the decade. Viking Therapeutics is heading toward the finish line with a drug that could compete with ...

At the time, Lily made it incredibly clear on her podcast, Miss Me?, that she was going through a pretty tough time. In January, she told listeners: “I’m finding it really hard to be interested in ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical trials was expected, the document still raised one concern for Eli Lilly’s ...

FILE - This photo shows Novo Nordisk headquarters in Bagsvaerd, Denmark, on Feb. 5, 2025. (Mads Claus Rasmussen/Ritzau Scanpix via AP, File) FILE - This photo shows Novo Nordisk headquarters in ...

Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 5.81% on an annualized basis producing an average annual return of 14.88%. Currently, Eli Lilly has a market capitalization ...

"I knew that the things I was feeling were too extreme to be able to manage," said Allen, who separated from ex David Harbour after four years of marriage Jack Irvin has over five years of experience ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker. Lilly said Thursday that its ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Charlotte Latin’s Jack Lilly is The Charlotte Observer’s high school boys’ athlete of the week. Lilly is a sophomore midfielder for ...

Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a candidate that could be a game-changer. Viking is a riskier-than-average stock, but ...